BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...
BioCentury | Feb 12, 2020
Finance

Moderna raises $500M, readies coronavirus vaccine for clinical testing

Moderna raised $500 million Tuesday after announcing that its coronavirus vaccine is ready for Phase I testing, and providing an update on other candidates in its antiviral vaccine pipeline. Moderna Inc. (NASDAQ:MRNA) sold 26.3 million...
BC Extra | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses. With 21 candidates spanning six treatment...
BC Week In Review | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
BC Extra | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
BC Week In Review | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BC Extra | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BC Week In Review | Nov 16, 2018
Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship...
BC Extra | Nov 10, 2018
Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering launched Moderna...
Items per page:
1 - 10 of 23